Brief: Novabay Pharmaceuticals Reports 2022 Fourth Quarter And Full Year Financial Results
March 30 (Reuters) - NovaBay Pharmaceuticals Inc
NBY.A :
* NOVABAY PHARMACEUTICALS REPORTS 2022 FOURTH QUARTER AND
FULL
YEAR FINANCIAL RESULTS
* NOVABAY PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $4.33
Source text for Eikon: ID:nBw74kRDDa
Further company coverage: NBY.A
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Stablecoin Development
See all newsBrief: Stablecoin Development Corporation Reports First Quarter 2026 Financial Results
Brief: Tether Says Participated In A $134 Million Financing Round For Stablecoin Development Corporation
Brief: Novabay Pharmaceuticals Announces Name Change To Stablecoin Development Corporation
Brief: Novabay Pharmaceuticals Says David Lazar Resigns As CEO
Brief: NovaBay Pharmaceuticals Files For Mixed Shelf Of Up To $200 Million - SEC Filing